Skip Navigation
Skip to contents

대한신장학회


간행물 검색

현재 페이지 경로
  • HOME
  • 간행물
  • 간행물 검색
논문분류 춘계학술대회 초록집
제목 Necrox-7 Improves Kidney Tissue Damage Caused by Fibrosis During Renal Ischemia-Reperfusion
저자 Young Rok Ham
출판정보 2024; 2024(1):
키워드
초록 Introduction: Ischemia-reperfusion injury (IRI) is a well-known cause of progression to renal fibrosis, a major pathologic symptom of chronic kidney disease (CKD). Ischemia-reperfusion (IR) increases inflammatory stimuli as CKD progresses, leading to ferroptosis and fibrosis. NecroX-7 was demonstrated to protect against necrosis and inflammation in virous organ injuries. In the present study, we evaluated whether NecroX-7 improves CKD-induced renal fibrosis through an anti-inflammatory response and reduction of reactive oxygen species in an IRI mouse model, and we investigated the mechanisms involved. Methods: C57BL/6 mice (eight weeks old, male) were divided into groups according to IR and NecroX-7 administration. IR was induced via 24-h renal IRI. One (1d), three (3d), or seven days (7d) after NecroX-7 treatment, kidney tissue and blood were collected. HK2 cell with TGF-β treatment are used for invitro studies. Results: Blood urea nitrogen and serum creatinine were both decreased in NecroX-7-treated IRI 3d and 7d mice compared with IRI 3d and 7d mice. Expression of F4/80, collagen IV, alpha smooth muscle actin, and transforming growth factor beta were all decreased and expression of E-cadherin was increased in the kidneys of NecroX-7-treated IRI 3d and 7d mice compared with IRI 3d and 7d mice. Anti-inflammatory, anti-ferroptosis, and antifibrotic protein expression were all increased in NecroX-7-treated IRI 3d and 7d mice compared with IRI 3d and 7d mice. In addition, lower levels of HMGB1 and nuclear factor kappa B were found in the kidneys of NecroX-7-treated IRI 3d and 7d mice than in IRI 3d and 7d mice. Conclusion: Our results confirmed that IR damages the kidneys and causes fibrosis. NecroX-7 functions as a protector against IRI-induced renal fibrosis in IRI mice.
원문(PDF) PDF 원문보기
위로가기